HLS Therapeutics Inc has seen a notable shift in its stock performance this week, with significant movements in its trading volume.
HLS Therapeutics Inc (HLS.TO) has recently experienced an 8.20% increase in its stock price over the past week, closing at C$4.03 on the latest trading day. Despite a slight drop of 1.45% on the most recent day, the overall trend suggests a recovery following earlier declines this year.
Investor takeaway: Investors are likely to keep a close eye on HLS Therapeutics as it expands its portfolio and reports financial results, which could influence future stock performance.
Advertisement
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$128.38M
52W high
$5.76
52W low
$3.56
1W change
+8.20%
Beta
0.83
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 79.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.35
+79.8% Upside
Current Price
C$4.09
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
43.6%
Annualized
90-Day Vol
32.5%
Annualized
Trend (90d)
-20.1%
Annualized drift
90d Mean
C$3.81
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.99 | C$3.44 – C$4.64 |
| 60 trading days | C$3.90 | C$3.15 – C$4.82 |
| 90 trading days | C$3.81 | C$2.93 – C$4.94 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
HLS Therapeutics Reports 8.20% Weekly Gain Amidst Volume Surge
The stock's trading volume has surged to 1,614 shares, significantly above the 20-day average of 73,372 shares, indicating heightened investor interest.
Bull case
The recent positive quarterly results and the expansion of the cardiovascular portfolio through licensing agreements could position HLS Therapeutics for growth and increased revenue. This expansion may lead to a stronger market presence and improved financial performance in the coming quarters.
Bear case
However, investors should be cautious due to a negative profit margin and a year-to-date decline of 15.67%. These factors raise concerns about the company's profitability and overall market performance, making it essential to weigh the risks before investing.
Recent Price Action
HLS Therapeutics Inc has closed at C$4.03, reflecting a 1.45% decrease on the last trading day. However, the stock has gained 8.20% over the past week, indicating a positive turn in investor sentiment.
Advertisement
Company News and Catalysts
The recent surge in HLS Therapeutics' stock can be attributed to its financial announcements. The company reported Q2 2026 revenue of $14.2 million and an Adjusted EBITDA of $5.2 million. Additionally, they expanded their cardiovascular portfolio by licensing Canadian rights to NEXLETOL® and NEXLIZET® from Esperion Therapeutics, which may enhance future growth potential.
Technical Picture
Analyzing the technical aspects, HLS Therapeutics is currently trading just slightly above its 50-day moving average of C$4.00, representing an increase of 0.8%. However, it remains below its 200-day moving average of C$4.43, indicating a 9.1% decline. The stock's 52-week trading range has been between C$3.56 and C$5.76, suggesting it is currently at 21% of its range. With a beta of 0.83, the stock is less volatile compared to the broader market.
Volume Insights
The recent trading volume for HLS Therapeutics has seen a significant spike, with the latest figure at 1,614 shares traded, which is 3.30 times the 20-day average volume of 73,372 shares. This increased volume reflects heightened interest among investors, which could be indicative of future price movements.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
